期刊文献+

食管癌靶向治疗药物应用现状 被引量:2

下载PDF
导出
摘要 食管癌是临床常见的消化系统恶性肿瘤,以吞咽不畅、咽部有异物感为主要临床症状.该病具有发病率及病死率高等特点,已成为危及患者健康和生命的危重疾病.相关研究证实,我国食管癌的发病率较高,约占世界发病例数的50%以上[1].因此,对食管癌治疗方法的研究已成为临床研究的重点课题.临床上常采用手术治疗,药物化疗,放射治疗及联合治疗等多种治疗方式,虽然具有显著的疗效,但因手术的创伤和放、化疗的不良反应,使得上述治疗的依从性较低[2].近年来,随着分子靶向治疗技术的发展,分子靶向治疗开始应用于食管癌的治疗,不仅确保了临床疗效,而且通过降低化疗药物的用量,降低治疗的不良反应,对提升临床疗效和治疗的依从性具有重要的意义[3].本文对临床采用靶向治疗食管癌的现状进行总结,为临床治疗及研究提供依据和参考.
作者 苟小军 李强
出处 《实用医药杂志》 2014年第3期266-268,共3页 Practical Journal of Medicine & Pharmacy
  • 相关文献

参考文献6

二级参考文献48

  • 1王慧霞,李继昌,杨德生,张正行,曹新广,李福春,秦宝山,金平.EGFR及β-catenin在食管鳞癌组织中的表达及临床意义[J].肿瘤基础与临床,2007,20(2):96-98. 被引量:4
  • 2Gibson MK,Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradio- therapy[J]. Clin Cancer Res, 2003, 9(17):6461-6468.
  • 3Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity [J]. Int J Radiat Oncol Biol Phys, 2008, 70(2):391-395.
  • 4Ku GY, Shah MA, Tang LH, et al. Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer[J]. J Clin Oncol, 2008, 26(Suppl):abstr 15580.
  • 5Safran H, DiPetrillo T, Akennan P, et al. Phase Ⅰ/Ⅱ study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2007, 67(2): 405-409.
  • 6Sato S, Kajiyama Y, Sugano M, et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein[J]. Int J Radiat Oncol Biol Phys, 2005, 61(1):203- 211.
  • 7Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase Ⅱ study of gefitinib in second-line treatment of advanced esophageal cancer patients[J]. J Clin Oncol, 2006, 24(34):5465.
  • 8Ferry DR, Anderson M, Beddard K, et al. A phase Ⅱ study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response[J]. Clin Cancer Res, 2007, 13(19): 5869-5875.
  • 9Dobelbower MC, Russo SM, Raisch KP, et al. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase Ⅰ study[J]. Anticancer Drugs, 2006, 17(1):95-102.
  • 10Tew WP, Shah M, Schwartz G, et al. Phase Ⅱ trial of erlotinib for second-line treatment in advanced esophageal cancer [A]. Proc Am Soc Clin Oncol GI Cancers Symposium[C]. New Orleans: ASCO, 2005. abstr 5.

共引文献89

同被引文献25

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部